Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications.
BACKGROUND
Diabetic vascular complications are leading causes of acquired blindness, end-stage renal failure, a variety of neuropathies, and accelerated atherosclerosis, which together could account for disabilities and high mortality rates in patients with diabetes. Since there is accumulating evidence that the advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress axis is involved in diabetic vascular complications, inhibition of the AGE-RAGE system may be a promising target for therapeutic intervention in these devastating disorders.


OBJECTIVE
In this review, we discuss several types of agent that may be able to inhibit the AGE-RAGE-oxidative stress system, and their therapeutic implications in vascular complications in diabetes.


METHODS
We have analyzed currently available scientific literature in the field of AGE-RAGE to create a comprehensive review on novel therapeutic agents for vascular complications in diabetes.


CONCLUSIONS
Inhibition of AGE formation, blockade of the AGE-RAGE interaction, and suppression of RAGE expression or its downstream pathways may be novel therapeutic strategies for the treatment of vascular complications in diabetes.
Yamagishi
Sho-Ichi
S
Kurume University School of Medicine, Department of Pathophysiology and Therapeutics of Diabetic Vascular Complications, Kurume, 67 Asahi-machi, Kurume 830-0011, Japan. shoichi@med.kurume-u.ac.jp
Nakamura
Kazuo
K
Matsui
Takanori
T
Ueda
Seiji
S
Fukami
Kei
K
Okuda
Seiya
S
D000818:Animals; D003925:Diabetic Angiopathies / Q000188:drug therapy* / Q000378:metabolism*; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D006801:Humans; D018384:Oxidative Stress / Q000187:drug effects*; D004364:Pharmaceutical Preparations; D011485:Protein Binding; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic / Q000378:metabolism*
D017127:Glycation End Products, Advanced; D004364:Pharmaceutical Preparations; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic